Cargando…
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
Non‐alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health because of high global prevalence and lack of evidence‐based therapies. Most animal models of NASH lack sufficient validation regarding disease progression and pharmacological treatment. The Gubra‐Amylin NASH (GA...
Autores principales: | Møllerhøj, Mathias B., Veidal, Sanne S., Thrane, Kirstine Tølbøl, Oró, Denise, Overgaard, Agnete, Salinas, Casper Gravesen, Madsen, Martin Rønn, Pfisterer, Larissa, Vyberg, Mogens, Simon, Eric, Broermann, Andre, Vrang, Niels, Jelsing, Jacob, Feigh, Michael, Hansen, Henrik H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099137/ https://www.ncbi.nlm.nih.gov/pubmed/35143711 http://dx.doi.org/10.1111/cts.13235 |
Ejemplares similares
-
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
por: Tølbøl, Kirstine S., et al.
Publicado: (2018) -
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
por: Tølbøl, Kirstine S, et al.
Publicado: (2018) -
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
por: Baandrup Kristiansen, Maria Nicoline, et al.
Publicado: (2019) -
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
por: Boland, Michelle L, et al.
Publicado: (2019) -
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)